Hodgkin's disease in childhood: therapy results in Argentina. 1981

F Sackmann-Muriel, and A C Bonesana, and S Pavlovsky, and C Papendieck, and M Morgenfeld, and L Penchansky, and L Schwartz, and R Kvicala, and M Sica, and F Ojeda

From 1940 to 1977, a total of 152 children aged 15 years or less with the histologic diagnosis of Hodgkin's disease were treated in Argentina. For analysis, these patients were placed into three periods which displayed the most outstanding changes in diagnostic workup and therapy. The periods are as follows: (1) 1940 to 1966 (43 children), (2) 1967 to 1972 (35 children), and (3) 1973 to 1977 (74 children). The patients were treated with extended field radiation therapy and followed by courses of cyclophosphamide-vinblastine-procarbazine-prednisone, with CCNU added (CCVPP) or not added (CVPP) in a randomized trial. The mean age of the whole group was 7.5 years (range 2 to 15 years) and there was a predominance of males (79%). Crude 6-year survival for the three periods were as follows: 1940 to 1966, 34%; 1967 to 1972, 50%; and 1973 to 1977, 79%. We conclude that (1) survival of Hodgkin's disease of childhood has shown a rather marked improvement during the last decade and this progress is probably due to the use of combined multidrug chemotherapy administered under collaborative controlled clinical trials; (2) preliminary evaluation of the results of CVPP and CCVPP therapy shows that the latter combination (CCVPP) neither increases the percent of patients achieving complete remission nor prolongs relapse-survival in Hodgkin's disease of childhood: and (3) all stages of childhood Hodgkin's disease can be successfully managed with multidrug chemotherapy alone.

UI MeSH Term Description Entries
D008130 Lomustine An alkylating agent of value against both hematologic malignancies and solid tumors. CCNU,Belustine,Cecenu,CeeNU,NSC-79037,NSC 79037,NSC79037
D008297 Male Males
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D011344 Procarbazine An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. Matulane,Natulan,Procarbazine Hydrochloride,Procarbazine Monohydrobromide,Procarbazine Monohydrochloride,Hydrochloride, Procarbazine,Monohydrobromide, Procarbazine,Monohydrochloride, Procarbazine
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

F Sackmann-Muriel, and A C Bonesana, and S Pavlovsky, and C Papendieck, and M Morgenfeld, and L Penchansky, and L Schwartz, and R Kvicala, and M Sica, and F Ojeda
April 1982, Archives francaises de pediatrie,
F Sackmann-Muriel, and A C Bonesana, and S Pavlovsky, and C Papendieck, and M Morgenfeld, and L Penchansky, and L Schwartz, and R Kvicala, and M Sica, and F Ojeda
November 1990, Deutsche medizinische Wochenschrift (1946),
F Sackmann-Muriel, and A C Bonesana, and S Pavlovsky, and C Papendieck, and M Morgenfeld, and L Penchansky, and L Schwartz, and R Kvicala, and M Sica, and F Ojeda
September 1958, Annals of the New York Academy of Sciences,
F Sackmann-Muriel, and A C Bonesana, and S Pavlovsky, and C Papendieck, and M Morgenfeld, and L Penchansky, and L Schwartz, and R Kvicala, and M Sica, and F Ojeda
May 1976, Monatsschrift fur Kinderheilkunde,
F Sackmann-Muriel, and A C Bonesana, and S Pavlovsky, and C Papendieck, and M Morgenfeld, and L Penchansky, and L Schwartz, and R Kvicala, and M Sica, and F Ojeda
January 1996, The oncologist,
F Sackmann-Muriel, and A C Bonesana, and S Pavlovsky, and C Papendieck, and M Morgenfeld, and L Penchansky, and L Schwartz, and R Kvicala, and M Sica, and F Ojeda
October 1989, Haematologica,
F Sackmann-Muriel, and A C Bonesana, and S Pavlovsky, and C Papendieck, and M Morgenfeld, and L Penchansky, and L Schwartz, and R Kvicala, and M Sica, and F Ojeda
June 1953, Archives of disease in childhood,
F Sackmann-Muriel, and A C Bonesana, and S Pavlovsky, and C Papendieck, and M Morgenfeld, and L Penchansky, and L Schwartz, and R Kvicala, and M Sica, and F Ojeda
December 1975, Cancer,
F Sackmann-Muriel, and A C Bonesana, and S Pavlovsky, and C Papendieck, and M Morgenfeld, and L Penchansky, and L Schwartz, and R Kvicala, and M Sica, and F Ojeda
January 1972, Padiatrie und Padologie,
F Sackmann-Muriel, and A C Bonesana, and S Pavlovsky, and C Papendieck, and M Morgenfeld, and L Penchansky, and L Schwartz, and R Kvicala, and M Sica, and F Ojeda
July 1977, The Indian journal of medical research,
Copied contents to your clipboard!